ImageneBio (IMA) Accumulated Expenses (2020 - 2025)
ImageneBio (IMA) posted Accumulated Expenses of $7.5 million for Q4 2025, up 9.14% sequentially from $6.9 million in Q3 2025, and up 117.72% YoY from $3.5 million in Q4 2024.
ImageneBio (IMA) Accumulated Expenses (2020 - 2025) Analysis & Trends
ImageneBio has reported Accumulated Expenses for 6 years, with the latest figure at $7.5 million in Q4 2025.
- Quarterly Accumulated Expenses rose 117.72% year-over-year to $7.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.5 million (up 117.72% YoY) and the FY2025 annual result came in at $7.5 million, up 117.72% from the prior year.
- Accumulated Expenses advanced to $7.5 million in Q4 2025 per IMA's latest filing, from $6.9 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $11.2 million in Q3 2023 and troughed at $3.0 million in Q2 2025.
- A 5-year average of $5.6 million and a median of $5.1 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 66.26% in 2024, then soared 117.72% in 2025.
- Over 5 years, Accumulated Expenses stood at $5.9 million in 2021, then jumped by 42.52% to $8.3 million in 2022, then gained by 2.85% to $8.6 million in 2023, then tumbled by 59.68% to $3.5 million in 2024, then jumped by 117.72% to $7.5 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $7.5 million, $6.9 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.53 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 3.09 Mn |
| Mar 31, 2024 | 4.82 Mn |
| Dec 31, 2023 | 8.58 Mn |
| Sep 30, 2023 | 11.19 Mn |
| Jun 30, 2023 | 6.46 Mn |
| Mar 31, 2023 | 5.42 Mn |
| Dec 31, 2022 | 8.34 Mn |
| Sep 30, 2022 | 8.68 Mn |
| Jun 30, 2022 | 5.35 Mn |
| Mar 31, 2022 | 4.33 Mn |
| Dec 31, 2021 | 5.85 Mn |
| Sep 30, 2021 | 4.23 Mn |
| Jun 30, 2021 | 3.77 Mn |
| Mar 31, 2021 | 3.56 Mn |